Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Combination therapy in cancer treatment Over time, the number of cancer clinical trials has risen, but the share of monotherapy trials has declined sharply (from around 70 percent to 20-30 percent).

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Researchers found that adding a third immune-targeting drug to existing therapies helped shrink tumors in lab models of ...

Immune checkpoint blockade medications have revolutionized cancer treatment, giving patients and providers new hope to control and sometimes cure metastatic cancer. However, predicting which patients ...

The efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.

A total of 1,091 patients with type 2 diabetes and HbA 1c levels of 7.5–11.0% were randomly assigned to receive combination therapy with daily sitagliptin (100 mg) and metformin (either 1,000 mg ...

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased ...

Discontinuation of antihypertensive combination therapy imposes a substantial public health burden, but few studies have addressed the factors associated with their discontinuation in Chinese ...

Combination therapy was shown to improve blood sugar control, boost kidney function and reduce weight gain. The findings, published in Nature Medicine, could help guide precision care for young type 1 ...